EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Combining CAR T-Cell Therapy and Nivolumab to Overcome Immune Resistance in THRLBCL: A Case Report

Daniel Munarriz, Oriana López-Godino, Nuria Martinez-Cibrian iD, Nil Albiol iD, Helena Brillembourg, Sergio Navarro-Velázquez, Marta Español-Rego, Sebastián Casanueva iD, Lucía García-Tomás, Guillermo Muñoz-Sanchez iD, Leticia Alserawan, Daniel Benitez-Ribas iD und 17 weitere

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26199265 ↗

Kurz gefasst

Fallbericht in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Daniel Munarriz und 28 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Hospital Clínic, 08036 Barcelona, Spain. Hauptthemen laut MEDLINE: Nivolumab, Lymphoma, Large B-Cell, Diffuse, Immunotherapy, Adoptive, Antineoplastic Agents, Immunological. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

T-cell/histiocyte-rich large B-cell lymphoma (THRLBCL) is a rare, aggressive subtype of diffuse large B-cell lymphoma characterized by a profoundly immunosuppressive tumor microenvironment. PD-L1 overexpression by tumor cells is a recognized immune escape mechanism and may underlie resistance to cellular therapies, including CAR T-cell therapy. We report a case of a 29-year-old woman with refractory stage IV-B THRLBCL treated with anti-CD19 CAR T-cell therapy (varnimcabtagene autoleucel), who achieved an initial response (day +28) but experienced disease progression by day +100 despite robust CAR T-cell expansion. Peripheral blood analysis revealed persistent absolute B-cell aplasia, while bone marrow biopsy confirmed CD19-positive disease. Comparative immunohistochemistry demonstrated markedly increased PD-L1 expression in post-CAR T-cell samples, suggesting adaptive immune resistance via PD-1/PD-L1-mediated CAR T-cell inhibition. Nivolumab was initiated at month +4 to overcome this checkpoint-mediated resistance. Notably, a complete metabolic response was documented on PET/CT after four doses of nivolumab (month +6). The patient remains in sustained remission, with persistent B-cell aplasia, four years post-intervention. This case provides clinical and pathological evidence supporting the use of immune checkpoint blockade to rescue CAR T-cell efficacy, highlighting the potential of this synergistic approach in THRLBCL and possibly other B-cell malignancies exhibiting similar immune evasion.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NivolumabLymphoma, Large B-Cell, DiffuseImmunotherapy, AdoptiveAntineoplastic Agents, ImmunologicalHumansFemaleAdultAntigens, CD19B7-H1 AntigenCombined Modality TherapyDrug Resistance, NeoplasmTumor Microenvironment

Stichwörter der Autor:innen

CAR-TCD19PD-1THRLBCLnivolumab

Substanzen

NivolumabAntineoplastic Agents, ImmunologicalAntigens, CD19B7-H1 Antigen

Autor:innen und Institutionen

  • Department of Hematology, Hospital Clínic, 08036 Barcelona, Spain.
  • Department of Hematology, Centro Regional de Hemodonación, IMIB-Pascual Parrilla, Hospital Universitario Morales-Meseguer, 30008 Murcia, Spain.
  • Faculty of Medicine, University of Barcelona, 08007 Barcelona, Spain.
  • Department of Immunology, Hospital Clínic, 08036 Barcelona, Spain.
  • Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain.
  • Department of Nuclear Medicine, Hospital C.U. Virgen de la Arrixaca, 30120 Murcia, Spain.

ORCID-Profile: Nuria Martinez-Cibrian, Nil Albiol, Sebastián Casanueva, Guillermo Muñoz-Sanchez, Daniel Benitez-Ribas, Andrea Rivero, Pablo Mozas, Europa Azucena González-Navarro, Manel Juan, Valentín Ortiz-Maldonado

Zitieren

APA

Munarriz, D., López-Godino, O., Martinez-Cibrian, N., Albiol, N., Brillembourg, H., Navarro-Velázquez, S., Español-Rego, M., Casanueva, S., García-Tomás, L., Muñoz-Sanchez, G., Alserawan, L., Benitez-Ribas, D., Magnano, L., Correa, J. G., Rivero, A., Mozas, P., Gine, E., Rodríguez-Lobato, L. G., Martínez-Roca, A., …, & Ortiz-Maldonado, V. (2025). Combining CAR T-Cell Therapy and Nivolumab to Overcome Immune Resistance in THRLBCL: A Case Report. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26199265

Vancouver

Munarriz D, López-Godino O, Martinez-Cibrian N, Albiol N, Brillembourg H, Navarro-Velázquez S, et al. Combining CAR T-Cell Therapy and Nivolumab to Overcome Immune Resistance in THRLBCL: A Case Report. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26199265

BibTeX
@article{Munarriz2025,
  author = {Munarriz, Daniel and López-Godino, Oriana and Martinez-Cibrian, Nuria and Albiol, Nil and Brillembourg, Helena and Navarro-Velázquez, Sergio and Español-Rego, Marta and Casanueva, Sebastián and García-Tomás, Lucía and Muñoz-Sanchez, Guillermo and Alserawan, Leticia and Benitez-Ribas, Daniel and Magnano, Laura and Correa, Juan Gonzalo and Rivero, Andrea and Mozas, Pablo and Gine, Eva and Rodríguez-Lobato, Luis Gerardo and Martínez-Roca, Alexandra and Montoro-Lorite, Mercedes and Ayora, Pilar and Esteve, Jordi and Frutos, Laura and Balagué-Ponz, Olga and Urbano-Ispizua, Alvaro and González-Navarro, Europa Azucena and Juan, Manel and Delgado, Julio and Ortiz-Maldonado, Valentín},
  title = {Combining CAR T-Cell Therapy and Nivolumab to Overcome Immune Resistance in THRLBCL: A Case Report},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26199265}
}
Kostenlos starten →